EL7.AI
CryptoMedium•18 November 2026•
4 min read

Nasdaq Lists Canary Staked INJ ETF Under Ticker INJC on Nov. 5

Key Facts

1The Canary Staked INJ ETF began trading on Nasdaq under the ticker INJC on Nov. 5, 2026.
2Injective’s on-chain order book recorded $12.86 billion in trading between Nov. 8, 2025 and Nov. 6, 2026.
3Trading in real-world-asset perpetual contracts approached $1.8 billion in the year ended Nov. 6, 2026.
4The fund’s prospectus sets an annual sponsor fee of 1.10% of its INJ holdings.

The Canary Staked INJ ETF began trading on Nasdaq under the ticker INJC on Nov. 5, 2026, according to an exchange notice, giving investors exposure to Injective through the brokerage accounts they use. Eric Chen, co-founder of the Injective Foundation, said investors can now gain exposure to INJ through their existing brokerage accounts. The fund aims to track the price of the INJ tokens it holds, with a secondary goal of earning additional tokens through staking, according to its registration statement filed with the U.S. Securities and Exchange Commission. Injective described the fund in its annual review as the first U.S. exchange-traded fund for INJ. The listing comes as digital-asset projects seek to offer exposure through financial products familiar to traditional investors.

BitGo Bank & Trust holds the fund’s INJ tokens in custody on its behalf, according to the registration statement. The statement sets an annual sponsor fee of 1.10% of the fund’s INJ holdings. Under normal circumstances, the sponsor intends to stake at least 90% of those holdings, but unstaking may take 21 days. The delay constrains how quickly assets can be made available when they need to be liquidated, according to the statement’s description of liquidity risks. Staking rewards are also subject to fees shared by the staking provider, sponsor and custodian, reducing the rewards received by the fund.

The fund’s launch comes as Injective expands its on-chain financial infrastructure, including tokenized real-world assets. The company said its new white paper, "A Layer-1 Blockchain Designed for Finance," was published in October 2026 and is its first complete rewrite of its white paper since 2018. The document presents the network as a layer 1 for issuing and using real-world assets across markets, applications and AI agents. The white paper therefore preceded the news of the fund listing and was not released alongside it. The company places the listing and white paper on separate tracks to expand its presence: one offers exposure to INJ through an investment product, while the other explains its vision for using the network in broader financial applications.

Figures published by Injective point to trading activity on its platform in the period leading up to the listing. Trading volume on its on-chain order book reached $12.86 billion between Nov. 8, 2025 and Nov. 6, 2026. In the year ended Nov. 6, 2026, trading in perpetual contracts linked to real-world assets approached $1.8 billion, with October the busiest month. The company says these contracts allow investors to take long or short positions in stocks, currencies, gold and oil at any time. The figures provide context on the network’s trading uses, but describe platform activity during the periods cited and do not measure the fund’s performance after its listing.

In a parallel development, Injective announced a partnership with the University of Tokyo’s Blockchain Innovation Chair. The company said the two sides will explore opportunities for collaboration on joint research, educational events and talent development. The chair is part of the university’s Graduate School of Engineering and was established in 2018. The company did not identify the integration of real-world assets as a stated goal of the partnership; the announcement focused on research, education and talent development. The partnership adds an academic connection to the company’s efforts, while the INJC listing remains a separate step that offers exposure to INJ through the securities market.

On what lies ahead for investment products tied to the token, Injective’s review said applications for funds from 21Shares and REX-Osprey remained under review. The review did not give a decision date for those applications. Daily closing data available at EL7 show INJ closed at $6.902 on Nov. 16, 2026, then at $7.422 on Nov. 17. These prices came after INJC began trading on Nov. 5, but they relate to the token itself and do not represent the fund’s share price or performance. The path for the other applications remains subject to the regulatory review cited by the company.

Open on chart